Insulin delivery for management of diabetes is a $1 billion+ global market. Delivery of insulin has evolved from simple syringes (which still represent a significant share of overall delivery device revenues) to the more convenient insulin pens to the emerging using of insulin pumps managed manually by diabetics or pumps integrated with glucose monitors as "artificial pancreases".
The goal of insulin delivery has long been to minimize the pain of administration, increase the convenience of delivery devices and, in general, move insulin delivery closer and closer to a method regulated by a homeostatic (biofeedback) system instead of a clinician- or patient-regulated method. Clinical data such as the large DCCT study have long been recognized to support the conclusion that more frequent and closer regulation of blood glucose via testing and dosing results in reduced risk of diabetic complications. Devices and instrumentation that facilitate more frequent and better regulation (i.e., reduction the pain, inconvenience and other hurdles to frequent glucose testing and insulin administration) have opportunistically capitalized on this, to the benefit of manufacturers.
The future market of diabetes management is indeed moving care toward scenarios in which technologies like an "artificial pancreas" may well represent the best alternative to a "cure" of diabetes. Such a system (e.g., from Medtronic) may well gain FDA approval in the next couple of years.
Below is the current distribution of this market among competitors supplying insulin delivery devices (including insulin syringes, pens and pumps).
Note: "Others" includes Ypsomed AG, Owen Mumford, Bioject Medical Technologies Inc., INJEX – Equidyne Systems (DBA) (Owned by HNS International), Antares Pharma, and Activa Brand Products, Inc.
Source: Report #D510, MedMarket Diligence, LLC.